Genmab (GMAB) announced updated results from two ongoing clinical trials evaluating the efficacy and safety of epcoritamab-bysp, a T-cell engaging antibody administered subcutaneously, as a monotherapy and in combination with other standard of care treatments in adult patients with diffuse large B-cell lymphoma and follicular lymphoma. Results from two arms of the EPCORE NHL-2 trial, evaluating first-line, fixed-treatment duration epcoritamab in combination with chemotherapies, demonstrated overall response rates of 93% and 98% in patients with newly-diagnosed DLBCL, while a third arm demonstrated a three-year overall survival rate of 96% in patients with FL following first-line combination treatment. In EPCORE DLBCL-3, the ORR was 73% in elderly patients with DLBCL treated with first-line, fixed-duration epcoritamab monotherapy who were unable to receive standard anthracycline-based chemotherapy. The study also showed that 54% of patients were progression free and 65% were alive at one year.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMAB:
- Genmab announces primary data from Phase 3 EPCORE FL-1 study
- Genmab A/S Discloses Managerial Share Transactions as of December 1, 2025
- Genmab A/S: Promising Growth Prospects with Strategic Catalysts and Robust Pipeline
- Genmab A/S Updates Articles of Association for Financial Flexibility
- Genmab Grants Stock Units and Warrants to Employees